INCYTE: Testing Time Ahead For JAKAFI

February 2012 | 3 pages | ID: ID261784022EN
MP Advisors

Abstracts

While the commercial challenge for Incyte (INCY) in US has just begun (reported only $2m net sales since its launch) for JAKAFI (ruxolitinib, approved, Myelofibrosis – MF, partnered with Novartis – Ex-US rights), we do not doubt the potential of the drug. JAKAFI targets “intermediate or high-risk” MF pts and as per market survey (done by INCY), 90% of physicians are willing to prescribe the drug based on its durable clinical benefits. However, with little physicians’ awareness or slow in acquiring a script, we expect the uptake to be steady and gradual. Besides MF, ruxolitinib is also being pursed in pts with advanced Polycythemia Vera, Essential Thrombocythemia, and in other hematologic and solid cancers. Data from couple of these trials are set to be out in 2012/13. PhIIb data of LY3009104 (formerly INCB28050, RA & Psoriasis, partnered with Eli Lilly) is expected at EULAR ’12 (3-mo data) and ACR ’12 (6-mo data) where convincing advantage of … For more details, please read our report released on February 28, 2012 on INCY, titled “Testing Time Ahead For JAKAFI”.

Contents

COMPANIES MENTIONED

INCYTE